C-Path Reaffirms Commitment to Advancing Regulatory Science for Disease-Modifying Therapies in Type 1 Diabetes
Regulatory milestone underscores opportunity for shared regulatory-science and evidence frameworks to support the next generation of therapies. TUCSON, Ariz., June 15, 2026 /PRNewswire/ -- Critical Path Institute® (C-Path), through its Type 1 Diabetes Consortium, today reaffirmed its...
Regulatory milestone underscores opportunity for shared regulatory-science and evidence frameworks to support the next generation of therapies. TUCSON, Ariz., June 15, 2026 /PRNewswire/ -- Critical Path Institute® (C-Path), through its Type 1 Diabetes Consortium, today reaffirmed its...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.